Skip to content
Clinical Trials – home
HungaryBack to Hungary

Clinical trials in Salgotarjan – page 4

270 clinical trials in Salgotarjan, Hungary. Every trial is listed in the EU Clinical Trials Register and updated daily.

Salgotarjan at a glance
270
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

270 trials in Salgotarjan

Open in trial search

Phase 3 Study of Subcutaneous vs Intravenous Tarlatamab with Siltuximab in Relapsed Extensive-Stage Small Cell Lung Cancer after Platinum Chemotherapy

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Siltuximab
  • Sponsor:Amgen Inc.

Long-Term Safety Study of Asciminib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bosutinib
  • Sponsor:Novartis Pharma AG

A study comparing the effectiveness and safety of datopotamab deruxtecan and docetaxel in adults with advanced or metastatic non-squamous non-small cell lung cancer

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Astrazeneca AB

Phase III trial evaluating ianalumab with background drug combination in patients with Sjögren's disease

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Emtricitabine
  • Sponsor:Novartis Pharma AG

Efficacy, safety and dose‑response of once‑weekly subcutaneous UBT251 compared with semaglutide in adults with type 2 diabetes

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Novo Nordisk A/S

Safety of PF-07872412 versus 20‑valent pneumococcal conjugate vaccine in healthy infants for prevention of pneumococcal disease

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:0–17 years
  • Substances:PF-07831695
  • Sponsor:Pfizer Inc.

Phase 3 Study of Romiplostim Combined with Prednisolone versus Prednisolone Alone in Adults with Previously Untreated Primary Immune Thrombocytopenia (ITP)

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Prednisolone
  • Sponsor:Amgen Inc.

Effect of elecoglipron plus dapagliflozin on cardiovascular outcomes in adults with heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF)

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:Astrazeneca AB

Efficacy and safety of lunsekimig in adults with inadequately controlled eosinophilic COPD: a randomized, double‑blind, placebo‑controlled trial

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Lunsekimig
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Long‑Term Safety and Tolerability of Oral Fesoterodine in Adults with Hallucinations and Delusions Due to Alzheimer’s Disease Psychosis

InvestigationalNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Betovumeline
  • Sponsor:Maplight Therapeutics Inc.

Crohn's disease

Recruiting

A Phase 3b Study of Guselkumab Compared with Risankizumab in Adults with Moderately to Severely Active Crohn’s Disease

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Guselkumab
  • Sponsor:Janssen - Cilag International

EIK1001, Pembrolizumab, and Chemotherapy for Stage 4 Non-Small Cell Lung Cancer in Patients with Stage 4 Non-Small Cell Lung Cancer

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Eikon Therapeutics Inc.

Other cities in Hungary

The busiest research cities in the country

All 73 cities in Hungary

Clinical research in Salgotarjan

What the registry says about research in the country

01 Breast Cancer Research

Innovative clinical trials focusing on hormone receptor-positive and HER2-negative breast cancer treatments, including studies of novel therapeutic combinations and targeted therapies.

  • Advanced metastatic breast cancer treatments
  • Triple-negative breast cancer therapies
  • Hormone therapy resistance studies

Research includes evaluation of new drug combinations and sequential therapy approaches for improved patient outcomes.

02 Lung Cancer Studies

Groundbreaking research on non-small cell lung cancer treatments, particularly focusing on advanced and metastatic cases with specific biomarker profiles.

  • PD-L1 positive NSCLC treatments
  • Combination immunotherapy approaches
  • Stage III unresectable cancer therapies

Studies emphasize personalized treatment approaches based on molecular markers.

03 Head and Neck Cancer

Clinical trials investigating new treatments for head and neck squamous cell carcinoma, including both HPV-negative and recurrent/metastatic cases.

  • Novel combination therapies
  • Immunotherapy applications
  • Treatment for recurrent disease

Research focuses on improving survival rates through innovative therapeutic combinations.

04 Prostate Cancer Innovations

Studies addressing metastatic castration-resistant prostate cancer, evaluating new treatment options and therapeutic combinations.

  • Novel hormonal therapies
  • Treatment-resistant cases
  • Combination therapy approaches

Trials aim to improve outcomes for patients with advanced disease stages.

05 Cardiovascular Research

Studies examining treatments for cardiovascular diseases and related conditions, including stroke prevention and obesity management.

  • Acute ischemic stroke treatments
  • Obesity management in CVD patients
  • Prevention strategies

Research focuses on both therapeutic interventions and preventive approaches.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.